Johan Hellgren
1 – 5 of 5
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Association Between Fatigue, Information Processing Speed and Plasma Levels of Glial Fibrillary Acidic Protein and Neurofilament Light in Patients With Relapsing–Remitting Multiple Sclerosis Treated With Natalizumab or Rituximab
Hellgren, Johan LU ; Compagno Strandberg, Maria LU ; Hansson, Oskar LU
; Janelidze, Shorena
LU
; Källén, Kristina
LU
and Svenningsson, Anders
(2026)
In Acta Neurologica Scandinavica
2026(1).
- Contribution to journal › Article
- 2025
-
Mark
Rituximab in multiple sclerosis - Fatigue, cognition, and efficacy
(2025) In Lund University, Faculty of Medicine Doctoral Dissertation Series
- Thesis › Doctoral thesis (compilation)
-
Mark
Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab
Hellgren, Johan LU ; Ahlström, Isabella ; Strandberg, Maria Compagno LU ; Jonsson, Magnus Förnvik LU
; Hansson, Oskar
LU
; Janelidze, Shorena
LU
; Svenningsson, Anders
and Källén, Kristina
LU
(2025)
In Multiple Sclerosis and Related Disorders
99.
- Contribution to journal › Article
- 2024
-
Mark
A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab
- Contribution to journal › Article
- 2020
-
Mark
Rituximab in multiple sclerosis at general hospital level
- Contribution to journal › Article